Avid Bioservices to Participate in Cambridge Healthtech Institute’s (CHI) 8th Annual The Bioprocessing Summit
August 09 2016 - 7:05AM
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine
Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced
that the company will have a significant presence at Cambridge
Healthtech Institute’s (CHI) 8th Annual The Bioprocessing Summit,
being held August 15-19, 2016 in Boston, MA. The company’s
vice president of process sciences, Pete Gagnon, will make a
presentation centered on the role of protein A in biomanufacturing
and will serve as one of three expert participants for a panel
discussion on technology advancements that can assist biological
drug manufacturers in achieving optimal viral clearance during the
performance of downstream purification processes.
Details of this presentation and panel
discussion are as follows:
|
|
|
Presentation Title: |
|
Protein A: the Untold Story |
Date: |
|
Thursday, August 16, 2016 |
Time: |
|
3:15 p.m. Eastern |
Panel Title: |
|
Improvements and Selection of Downstream Viral
Clearance Technology |
Date: |
|
Thursday, August 16, 2016 |
Time: |
|
4:15 p.m. Eastern |
Participants: |
|
Pete Gagnon, Vice President, Process Sciences,
Avid Bioservices Inc. Arifa Khan, Ph.D., Supvy Microbiologist,
Viral Products, FDA CBERMark Plavsic, Ph.D., Senior Director,
Product Biosafety, Industrial Operations, Sanofi |
|
|
|
In addition, Avid will host a corporate booth
(#200) in the conference’s exhibit hall where it will showcase the
company’s comprehensive range of process development, high quality
cGMP clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. These include
a variety of innovative processes for generating a broad range of
biopharmaceutical product types such as monoclonal antibodies,
highly-glycosylated recombinant proteins and enzymes, among
others. These capabilities also extend to the manufacture of
biosimilar products and are designed to support the overall ongoing
growth of the company’s contract manufacturing business.
Avid will also provide a virtual tour of
Peregrine’s recently-commissioned 40,000 square foot
state-of-the-art commercial biomanufacturing suite (Myford
facility), which is operated by Avid. The Myford facility is
designed to utilize the most cutting-edge, single-use equipment to
accommodate a fully disposable biomanufacturing process for late
Phase III clinical and commercial production of biologics.
The facility is capable of operating in campaign mode whereby
multiple bioreactors are simultaneously in operation, which
improves the facility’s manufacturing capacity and
efficiency. The recently commissioned Myford facility has
completed an initial process validation campaign with a second
process validation currently underway and two more planned for
later this year.
Furthermore, in response to demand for
manufacturing services, Peregrine is now designing a third
manufacturing facility dedicated to clinical manufacturing that
will significantly increase Avid’s manufacturing capacity.
The new clinical suite is expected to be complete and ready for
clinical phase manufacturing activities by
mid-2017.
For more information on CHI’s 8th Annual The
Bioprocessing Summit, please visit:
http://www.bioprocessingsummit.com/
About Avid BioservicesAvid Bioservices provides
a comprehensive range of process development, high quality cGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With over 15 years
of experience producing monoclonal antibodies and recombinant
proteins in batch, fed-batch and perfusion modes, Avid's services
include cGMP clinical and commercial product manufacturing,
purification, bulk packaging, stability testing and regulatory
strategy, submission and support. The company also provides a
variety of process development activities, including cell line
development and optimization, cell culture and feed optimization,
analytical methods development and product characterization. For
more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a biopharmaceutical
company committed to improving the lives of patients by delivering
high quality pharmaceutical products through its contract
development and manufacturing organization (CDMO) services and
through advancing and licensing its investigational immunotherapy
and related products. Peregrine's in-house CDMO services,
including cGMP manufacturing and development capabilities, are
provided through its wholly-owned subsidiary Avid Bioservices, Inc.
(www.avidbio.com), which provides development and biomanufacturing
services for both Peregrine and third-party customers. The
company is also working to evaluate its lead immunotherapy
candidate, bavituximab, in combination with immune stimulating
therapies for the treatment of various cancers, and developing its
proprietary exosome technology for the detection and monitoring of
cancer. For more information, please visit
www.peregrineinc.com.
Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2024 to May 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From May 2023 to May 2024